menu search

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in science advances demonstrating potent in vitro and in vivo antimicrobial activity

Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial f...

June 7, 2023, 5:15 am

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in science advances demonstrating potent in vitro and in vivo antimicrobial activity

Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial f...

June 7, 2023, 5:15 am

Araris biotech supported with chf 2.5m swiss accelerator grant from innosuisse to develop antibody-drug conjugate candidates

The Swiss Accelerator programme’s total funding grant amounted to CHF 112M (~$125 million) with support per project amounting to a maximum of CHF 2....

May 8, 2023, 4:44 am

Araris biotech ag supported with chf 2.5m swiss accelerator grant from innosuisse to develop antibody-drug conjugate candidates

innosuisse supports 53 companies out of 752 applications with total CHF 112M Araris’ awarded grant wi...

May 5, 2023, 6:14 am


Search within

Pages Search Results: